Relocalization of KIT D816V to cell surface after dasatinib treatment: Potential clinical implications

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 1, 2013, Pages 62-69

  Bougherara, Houcine ^a   Georgin Lavialle, Sophie ^b,c   Damaj, Gandhi ^d   Launay, Jean Marie ^e   Lhermitte, Ludovic ^b,f   Auclair, Christian ^a   Arock, Michel ^a   Dubreuil, Patrice ^g   Hermine, Olivier ^a,b,f   Poul, Marie Alix ^a,h  

^a Ecole Normale Superieure de Cachan   (France)

^b CNRS   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e HÔPITAL LARIBOISIÈRE   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g AIX MARSEILLE UNIVERSITY   (France)

^h INSERM   (France)

Author keywords

Dasatinib; KIT cell surface detection; KIT mutation; Systemic mastocytosis; Tyrosine kinase inhibitor

Indexed keywords

DASATINIB;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CELL LINEAGE; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HYPOTHESIS; MALE; MAST CELL; MASTOCYTOMA; MONONUCLEAR CELL; POINT MUTATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SYSTEMIC MASTOCYTOSIS; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL MEMBRANE; FEMALE; HUMANS; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; THIAZOLES; YOUNG ADULT;

EID: 84873297013     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.08.004     Document Type: Article

References (19)

1. P. Valent, C. Akin, L. Escribano Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria Eur J Clin Invest 37 2007 435 453
2. P. Valent, H.P. Horny, L. Escribano Diagnostic criteria and classification of mastocytosis: a consensus proposal Leuk Res 25 2001 603 625
3. F. Lanternier, A. Cohen-Akenine, F. Palmerini Phenotypic and genotypic characteristics of mastocytosis according to the age of onset PLoS ONE 3 2008 e1906
4. C. Bodemer, O. Hermine, F. Palmérini Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations J Invest Dermatol 130 2010 804 815
5. L. Escribano, B. Díaz-Agustín, C. Bellas Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis Leuk Res 25 2001 563 570
6. L. Escribano, B. Diaz-Agustin, A. López Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it Proposals of the Spanish network on mastocytosis (REMA) Cytometry B Clin Cytom 58 2004 1 8
7. C. Teodosio, A.C. García-Montero, M. Jara-Acevedo Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes J Allergy Clin Immunol 125 2010 719 726 726, e1-726 e4
8. S. Georgin-Lavialle, L. Lhermitte, C. Baude Blood CD34-c-Kit+ cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor Blood 118 2011 5246 5249
9. M.J. Frost, P.T. Ferrao, T.P. Hughes Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant Mol Cancer Ther 1 2002 1115 1124
10. H. Bougherara, F. Subra, R. Crépin The aberrant localization of oncogenic Kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment Mol Cancer Res 7 2009 1525 1533
11. P. Valent, H.P. Horny, L. Escribano, B.J. Longley Mastocytosis (mast cell disease) World Health Organization (WHO) Classification of Tumours; 1 2001 IARC Lyon, France 291 302
12. L. Escribano, A. Orfao, B. Dìaz-Augustìn Indolent Systemic Mast Cell Disease in Adults: Immunophenotypic Characterization of Bone Marrow Mast Cells and its Diagnostic Implications Blood 98 1998 2731 2736
13. S. Verstovsek, A. Tefferi, J. Cortes Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis Clin Cancer Res 14 2008 3906 3915
14. C. Ustun, C.L. Corless, N. Savage Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT Leuk Res D816V:33 2009 735 741
15. A. Hochhaus, H.M. Kantarjian, M. Baccarani Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy Blood 109 2007 2303 2309
16. J. Gotlib, C. Bérubé, J.D. Growney Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation Blood 106 2005 2865 2870
17. S. Tabone-Eglinger, F. Subra, H. El Sayadi KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors Clin Cancer Res 14 2008 2285 2294
18. C. Choudhary, J.V. Olsen, C. Brandts Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes Mol Cell 36 2009 326 339
19. P. Mazot, A. Cazes, M.C. Boutterin The constitutive activity of the ALK mutated at positions F1174 or R 1275 Impairs receptor trafficking Oncogene 30 2011 2017 2025